Get started
Author

Feng Hao

Observed name: Feng B. Hao
ORCID: 0000-0002-6057-1097
Observed ORCID: 0000-0002-6057-1097
OpenAlex ID: A5040251310
Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96
2024 · Randa Mahran, Jonas N. Kapp, et al. · ACS Chemical Biology · 23
PDF
Design, Synthesis, and Biological Evaluation of Novel Fms-Like Tyrosine Kinase 3/VEGFR2/Histone Deacetylase Inhibitors for the Treatment of Acute Myeloid Leukemia
2025 · Hua Tian, Yichen Liu, et al. · Journal of Medicinal Chemistry · 17
Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
2024 · Lanlan Pang, Yihua Huang, et al. · Clinical Cancer Research · 12
PDF
The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
2026 · Jiani Zheng, Shen Zhao, et al. · Cancer Discovery · 2
Abstract 5679: A novel approach for antibody affinity maturation using AI-driven mutation prediction
2025 · Yiran Li, Hao Peng, et al. · Cancer Research · 2
Abstract 368: Neutralizing antibody against GDF-15 restores cachexia
2023 · Feng He, Hao Peng, et al. · Cancer Research · 2
Abstract 5981: Over 200! The largest BaF3-EGFR engineering cell lines collection, a useful platform for novel drug discovery
2025 · Yao Tang, Guoqian Wang, et al. · Cancer Research · 1
Abstract 4189: CRISPR-edited cell lines targeting key molecular pathways: Accelerating the development of synthetic lethal therapeutics beyond PARP inhibitors
2025 · Yue Huang, Yunpeng Zhai, et al. · Cancer Research · 1
Abstract 6365: The bispecific antibody KA-3008, targeting both EGFR and B7H3, increases internalization and minimizes on-target, off-tumor toxicity
2024 · Guojin Wu, Li Ding, et al. · Cancer Research · 1
Abstract 1677: ASPC-1-MRTX-1133R as a useful cell line model for KRAS-G12D inhibitor development
2023 · Guoqian Wang, Yao Tang, et al. · Cancer Research · 1
Abstract 593: Bispecific antibody against TIGIT and PVRIG enhances antitumor immunity
2023 · Jiabei Liang, Xiao Gao, et al. · Cancer Research · 1
Abstract 6207: Ba/F3 kinase mutant cell panel, a powerful cell model for the discovery and development of inhibitors for kinase specific mutation
2022 · Yu Wang, Yao Peng, et al. · Cancer Research · 1
Bispecific antibodies targeting TL1A and IL-12/23p40 suppress pathogenic Th1/Th17 responses and ameliorate colitis in mice
2026 · Xia Li, Hao Peng, et al. · iScience
Supplementary Table S3 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
2026 · Jiani Zheng, Shen Zhao, et al.
Supplementary Table S2 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
2026 · Jiani Zheng, Shen Zhao, et al.
Supplementary Figure S4 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
2026 · Jiani Zheng, Shen Zhao, et al.
Data from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
2026 · Jiani Zheng, Shen Zhao, et al.
Supplementary Figure S2 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
2026 · Jiani Zheng, Shen Zhao, et al.
Supplementary Figure S3 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
2026 · Jiani Zheng, Shen Zhao, et al.
Supplementary Table S4 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
2026 · Jiani Zheng, Shen Zhao, et al.
Supplementary Table S1 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
2026 · Jiani Zheng, Shen Zhao, et al.
Supplementary Figure S5 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
2026 · Jiani Zheng, Shen Zhao, et al.
Supplementary Figure S1 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
2026 · Jiani Zheng, Shen Zhao, et al.
Abstract 741: Illuminate your targets: Endogenous HiBiT knock-in monoclones—inventory + rapid custom.
2026 · Xiaomeng Gou, Yue Huang, et al. · Cancer Research
Abstract 7537: From BTK in-situ mutation (C481S, A428D, etc.) to in vivo screening: A comprehensive platform to address drug resistance in BTK-targeted therapy
2026 · Yao Tang, Guoqian Wang, et al. · Cancer Research
Works count: 76
Citation count: 64
H-index: 3
I10-index: 3
Year
Topic
Type